FIELD: chemistry.
SUBSTANCE: active metabolite of 5-bromo-2.6-di(1H-pyrazol-1-yl)pyrimidin-4-amine, which is the compound 1-(4-amino-5-bromo-6-(1H-pyrazol-1-yl)pyrimidin-2-yl)-1H-pyrazol-4-ol of the following formula. A pharmaceutical composition and a combination are proposed containing 1-(4-amino-5-bromo-6-(1H-pyrazol-1-yl)pyrimidin-2-yl)-1H-pyrazol-4-ol and method for inhibiting the A2a adenosine receptor in a subject.
EFFECT: modeling of the A2a adenosine receptor and use in cancer treatment alone or in combination with one or more immunotherapeutic agents.
6 cl, 4 dwg, 15 tab, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| 5-BROMO-2,6-DI - (1H-PYRAZOL-1-YL)PYRIMIDINE-4-AMINE FOR USE IN CANCER TREATMENT | 2016 |
|
RU2745560C2 |
| MOLECULES OF ANTIBODIES TO PD-1 AND THEIR USE | 2016 |
|
RU2788092C2 |
| 3-(5-AMINO-1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND USE THEREOF IN TREATING DISEASES ASSOCIATED WITH ZINC FINGER PROTEIN 2 OF IKAROS (IKZF2) FAMILY | 2019 |
|
RU2815714C2 |
| ANTIBODIES TO PD-1 AND THEIR APPLICATION | 2017 |
|
RU2761640C2 |
| ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2788095C2 |
| ANTIBODIES TO DOGS' PD-1 | 2014 |
|
RU2732604C2 |
| TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
| HYBRID PROTEINS OF sPD-1-Fc VARIANT | 2019 |
|
RU2785993C2 |
| ANTI-CANINE CTLA-4 ANTIBODY | 2020 |
|
RU2818586C2 |
| CANINIZED ANTI-HUMAN CTLA-4 ANTIBODIES | 2020 |
|
RU2822460C2 |
